Bank of Montreal Can Boosts Stock Holdings in Henry Schein, Inc. (NASDAQ:HSIC)

Bank of Montreal Can raised its holdings in Henry Schein, Inc. (NASDAQ:HSIC - Free Report) by 365.6% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 711,487 shares of the company's stock after buying an additional 558,689 shares during the period. Bank of Montreal Can owned about 0.57% of Henry Schein worth $52,095,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the business. Daiwa Securities Group Inc. lifted its holdings in Henry Schein by 11.4% during the 3rd quarter. Daiwa Securities Group Inc. now owns 15,636 shares of the company's stock valued at $1,140,000 after purchasing an additional 1,596 shares during the last quarter. Cerity Partners LLC grew its position in shares of Henry Schein by 12.3% during the 3rd quarter. Cerity Partners LLC now owns 26,339 shares of the company's stock worth $1,920,000 after purchasing an additional 2,894 shares in the last quarter. Studio Investment Management LLC grew its position in shares of Henry Schein by 3.8% during the 3rd quarter. Studio Investment Management LLC now owns 4,674 shares of the company's stock worth $341,000 after purchasing an additional 172 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in shares of Henry Schein by 0.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,175,061 shares of the company's stock worth $85,662,000 after purchasing an additional 6,184 shares in the last quarter. Finally, Thompson Siegel & Walmsley LLC grew its position in shares of Henry Schein by 37.7% during the 3rd quarter. Thompson Siegel & Walmsley LLC now owns 1,003,041 shares of the company's stock worth $73,122,000 after purchasing an additional 274,756 shares in the last quarter. 96.62% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, COO Michael S. Ettinger sold 12,240 shares of the company's stock in a transaction on Monday, November 18th. The stock was sold at an average price of $75.00, for a total transaction of $918,000.00. Following the completion of the sale, the chief operating officer now owns 87,706 shares in the company, valued at approximately $6,577,950. This represents a 12.25 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Lorelei Mcglynn sold 21,035 shares of the firm's stock in a transaction on Friday, September 6th. The shares were sold at an average price of $69.30, for a total value of $1,457,725.50. Following the transaction, the senior vice president now owns 71,833 shares in the company, valued at approximately $4,978,026.90. This trade represents a 22.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 1.14% of the company's stock.

Henry Schein Trading Up 0.5 %

Shares of HSIC stock traded up $0.38 during trading hours on Thursday, hitting $77.66. 832,776 shares of the company's stock traded hands, compared to its average volume of 1,400,600. The stock's 50 day simple moving average is $71.26 and its 200 day simple moving average is $69.84. The stock has a market cap of $9.68 billion, a PE ratio of 31.96, a price-to-earnings-growth ratio of 2.20 and a beta of 0.87. Henry Schein, Inc. has a 12 month low of $63.67 and a 12 month high of $82.63. The company has a quick ratio of 0.82, a current ratio of 1.42 and a debt-to-equity ratio of 0.46.

Henry Schein (NASDAQ:HSIC - Get Free Report) last posted its quarterly earnings data on Tuesday, November 5th. The company reported $1.22 earnings per share for the quarter, topping the consensus estimate of $1.17 by $0.05. Henry Schein had a net margin of 2.51% and a return on equity of 12.90%. The company had revenue of $3.17 billion during the quarter, compared to analysts' expectations of $3.24 billion. During the same period in the prior year, the company posted $1.32 earnings per share. Henry Schein's revenue for the quarter was up .4% compared to the same quarter last year. On average, sell-side analysts anticipate that Henry Schein, Inc. will post 4.78 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on HSIC shares. JPMorgan Chase & Co. decreased their target price on shares of Henry Schein from $88.00 to $80.00 and set an "overweight" rating on the stock in a research report on Monday, August 12th. Barrington Research restated an "outperform" rating and set a $82.00 target price on shares of Henry Schein in a research report on Wednesday, November 6th. UBS Group cut their price target on shares of Henry Schein from $75.00 to $72.00 and set a "neutral" rating for the company in a report on Wednesday, August 7th. Robert W. Baird dropped their price objective on shares of Henry Schein from $92.00 to $82.00 and set an "outperform" rating for the company in a research note on Wednesday, August 7th. Finally, Evercore ISI increased their price objective on shares of Henry Schein from $70.00 to $74.00 and gave the company an "in-line" rating in a research note on Tuesday, October 8th. Six analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $79.38.

Henry Schein Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.